Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer.

Abstract: Disclosed is an application of methioninase gene therapy in the treatment of a malignant tumor. In the gene therapy, a virus is used as a vector to insert an exogenous methioninase gene to constitute a methioninase expression system inside a tumor, thus providing an endogenous mechanism for further consumption of methionine. In vitro cytology experiments indicate that the methioninase gene therapy significantly reduces the level of intracellular methionine, effectively inhibits the proliferation of tumor cells, and can be used in an application in preparing a drug for the targeted treatment of a malignant tumor.

Abstract: A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases.

Abstract: Disclosed in the present disclosure are a potassium salt crystal form B of a phosphodiesterase type 5 inhibitor, and a preparation method and a use therefor. The structural formula of the phosphodiesterase type 5 inhibitor is as shown in a formula (I), and the X-ray powder diffraction (XRPD) pattern of the potassium salt crystal form B has characteristic peaks at the following 2? angles: 5.71°±0.2°, 8.23°±0.2°, 11.37°±0.2°, 13.22°±0.2°, 17.09°±0.2°, 21.56°±0.2°, 23.99°±0.2°, and 25.85°±0.2°. Further disclosed in the present disclosure is a use for the present crystal form potassium salt in preparing drugs for treating pulmonary hypertension, idiopathic pulmonary fibrosis, renal fibrosis, myocardial hypertrophy, or erectile dysfunction.

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating malignant sarcoma.

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: Provided are a viral vector for treating autoimmune disease and diabetes and a construction method and an application thereof. The viral vector is a lentiviral expression plasmid or an adeno-associated viral expression plasmid cloned with mfat-1 gene, and the mfat-1 gene is as shown in SEQ ID NO: 1.

Abstract: The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application.

Abstract: Provided is use of a genetically engineered bacterium of attenuated Salmonella typhimurium for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer.

Abstract: Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating malignant sarcoma.

Abstract: The present invention discloses a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 for applications in preparing drugs for treating proliferation and metastasis of prostate cancer. The animal experiments and cytological experiments in mice showed that the PDE4 inhibitor ZL-n-91 of the present invention can significantly inhibit the proliferation and metastasis of prostate cancer cells, indicating that the PDE4 inhibitor ZL-n-91 is expected to be an important target for treating proliferation and metastasis of prostate cancer. It will lay a foundation for preparing drugs against proliferation and metastasis of prostate cancer, presenting good prospect for development and application.

Abstract: The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application.

Abstract: Provided is an application of a genetically engineered bacterium of attenuated Salmonella typhimurium in preparation of medicines for treating liver cancer. The bacterium is attenuated Salmonella typhimurium VNP20009 carrying a plasmid cloned with a methioninase gene. Also provided is a construction method of the bacterium.

Abstract: It discloses a transformant for weight loss and lipid reduction, which is obtained by recombining and substituting human oxyntomodulin gene into thymidylate synthase gene of L.lactis genome. Wherein the recombinant substitution is homologous recombination by artificially synthesizing gene sequences, making the sequence flanking the human oxyntomodulin gene derived from the homologous sequences of thymidylate synthase gene in the L.lactis genome, then the gene fragments are electroporated into L. lactis, to carry out homologous recombination.

Abstract: It discloses a transformant for weight loss and lipid reduction, which is obtained by recombining and substituting human oxyntomodulin gene into thymidylate synthase gene of L. lactis genome. Wherein the recombinant substitution is homologous recombination by artificially synthesizing gene sequences, making the sequence flanking the human oxyntomodulin gene derived from the homologous sequences of thymidylate synthase gene in the L. lactis genome, then the gene fragments are electroporated into L. lactis, to carry out homologous recombination.

Abstract: The current invention discloses an attenuated Salmonella typhimurium, a genetically engineered bacterium and applications thereof in preparing drugs for the treatment of prostate cancer. The attenuated Salmonella typhimurium has tumor targeting and significant inhibitory effects on prostate cancer cells. A genetically engineered bacterium bearing a L-methioninase gene plasmid also has tumor targeting ability. The attenuated Salmonella typhimurium with the plasmid can constitutively express L-methioninase in the tumor tissues, consume a significant amount of methionine and other nutrients, which in turn causes lack of nutrition and slow growth of tumor cells. Therefore, it can be used as drugs for treating prostate cancer.